136 related articles for article (PubMed ID: 38234854)
1. KMT2A oncoproteins induce epigenetic resistance to targeted therapies.
Janssens DH; Duran M; Otto DJ; Kirkey D; Yi JS; Meshinchi S; Sarthy JF; Ahmad K; Henikoff S
bioRxiv; 2023 Dec; ():. PubMed ID: 38234854
[TBL] [Abstract][Full Text] [Related]
2. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in
Adriaanse FRS; Schneider P; Arentsen-Peters STCJM; Fonseca AMND; Stutterheim J; Pieters R; Zwaan CM; Stam RW
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892207
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.
Kwon MC; Thuring JW; Querolle O; Dai X; Verhulst T; Pande V; Marien A; Goffin D; Wenge DV; Yue H; Cutler JA; Jin C; Perner F; Hogeling SM; Shaffer PL; Jacobs F; Vinken P; Cai W; Keersmaekers V; Eyassu F; Bhogal B; Verstraeten K; Ashkar SE; Perry JA; Jayaguru P; Barreyro L; Kuchnio A; Darville N; Krosky D; Urbanietz G; Verbist B; Edwards JP; Cowley GS; Kirkpatrick R; Steele R; Ferrante L; Guttke C; Daskalakis N; Pietsch EC; Wilson DM; Attar RM; Elsayed YA; Fischer ES; Schuringa JJ; Armstrong SA; Packman K; Philippar U
Blood; 2024 Jun; ():. PubMed ID: 38905635
[TBL] [Abstract][Full Text] [Related]
4. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
Candoni A; Coppola G
Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
[TBL] [Abstract][Full Text] [Related]
5. Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia.
Janssens DH; Meers MP; Wu SJ; Babaeva E; Meshinchi S; Sarthy JF; Ahmad K; Henikoff S
Nat Genet; 2021 Nov; 53(11):1586-1596. PubMed ID: 34663924
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
Thomas X
Oncol Ther; 2024 Mar; 12(1):57-72. PubMed ID: 38300432
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
[TBL] [Abstract][Full Text] [Related]
9. Updates in
Górecki M; Kozioł I; Kopystecka A; Budzyńska J; Zawitkowska J; Lejman M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979800
[TBL] [Abstract][Full Text] [Related]
10. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S; Shukla N; Kantarjian H; Armstrong SA; Perner F; Perry JA; Rosen G; Bagley RG; Meyers ML; Ordentlich P; Gu Y; Kumar V; Smith S; McGeehan GM; Stein EM
Nature; 2023 Mar; 615(7954):920-924. PubMed ID: 36922593
[TBL] [Abstract][Full Text] [Related]
11. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
[TBL] [Abstract][Full Text] [Related]
12. MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Gindin T; Murty V; Alobeid B; Bhagat G
Hematol Oncol; 2015 Dec; 33(4):239-46. PubMed ID: 25131304
[TBL] [Abstract][Full Text] [Related]
13. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
16. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
[TBL] [Abstract][Full Text] [Related]
17. Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Kingsley MC; Xie HM; Chen BR; Riedel SS; Pastuer T; Bollig MK; Shank T; Libbrecht C; Stabler SP; Deshpande AJ; Intlekofer AM; Bernt KM
Blood Adv; 2020 Jul; 4(13):3109-3122. PubMed ID: 32634241
[TBL] [Abstract][Full Text] [Related]
18. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
19. Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia.
Xing Z; Mai H; Liu X; Fu X; Zhang X; Xie L; Chen Y; Shlien A; Wen F
Genome Biol; 2022 Aug; 23(1):173. PubMed ID: 35945623
[TBL] [Abstract][Full Text] [Related]
20. Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P; Crump NT; Arentsen-Peters STCJM; Smith AL; Hagelaar R; Adriaanse FRS; Bos RS; de Jong A; Nierkens S; Koopmans B; Milne TA; Pieters R; Stam RW
Exp Hematol Oncol; 2023 Sep; 12(1):81. PubMed ID: 37740239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
